MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s patients.
Cell & Gene Therapy
Terumo and Charles River demonstrate effectiveness of CGT manufacturing device
Advancing quality control measures vital for cell and gene therapy development
NHS investment critical to drive cell and gene therapy research
Gene therapy for rare neuropathy displays potential in NIH trial
Can Gilead shake up the ASCT-ineligible large B-cell lymphoma market?
Mapping endpoints: building gene therapy trials for the future
Five gene therapy trial readouts to watch in the first half of 2023
